FilingSEC EDGAR8-K
Gossamer Bio Submits NDA for Seralutinib
· SEC accepted
StageNDA Submission
Filing content
The company submitted a New Drug Application to the FDA for seralutinib for the treatment of pulmonary arterial hypertension, supported by Phase 3 data.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…